CLINICAL TRIAL

EGFRt/19-28z/4-1BBL CAR T cells for Hematologic Neoplasms

Waitlist Available · 18+ · All Sexes · New York, NY

This study is evaluating whether modified T cells are safe for patients with this type of cancer.

See full description

About the trial for Hematologic Neoplasms

Eligible Conditions
Chronic Lymphocytic Leukemia (CLL) · relapsing · Refractory · Leukemia, Lymphocytic, Chronic, B-Cell · Hematologic Neoplasms

Treatment Groups

This trial involves 2 different treatments. EGFRt/19-28z/4-1BBL CAR T Cells is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
EGFRt/19-28z/4-1BBL CAR T cells
BIOLOGICAL
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Hematologic Neoplasms or one of the other 4 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Refractory to or relapsed after at least 2 prior chemo or chemoimmunotherapy (e.g. FCR, BR) requiring further treatment
Refactory to or relapsed after at least 1 prior biologic agent (e.g. Ibrutinib, idelalisib, venetoclax, except a single agent anti-CD20 monoclonal antibody) requiring further treatment
Refractory or relapsed after at least 2 lines of chemoimmunotherapy (including at least one course of anti-CD20 antibody)
Refractory or relapsed after at least 1 prior biologic agent (e.g. lenalidomide, ibrutinib, idelalisib)
Patients must have measurable disease (for WM patients, measureable disease is demonstrable monoclonal paraprotein and bone marrow involvement)
Refractory to or relapsed after 1 or more prior chemoimmunotherapies with at least one containing an anthracycline and CD20 directed therapy
Transplant ineligible
Biopsy proven relapsed disease
Refractory to at least 1 prior induction chemotherapy
Relapsed after at least 1 prior multiagent systemic chemotherapy that included induction and consolidation
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: occurring within 30 days from the last infusion
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: occurring within 30 days from the last infusion.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether EGFRt/19-28z/4-1BBL CAR T cells will improve 1 primary outcome in patients with Hematologic Neoplasms. Measurement will happen over the course of occurring within 30 days from the last infusion.

Maximum tolerated dose (MTD)
OCCURRING WITHIN 30 DAYS FROM THE LAST INFUSION
Cohorts of 3-6 patients each will be treated with escalating doses of modified T cell. At least 3 patients will be treated at each dose level with an accrual of no more than 2 patients per month within each dose level. At least two weeks will elapse from the first patient's T cell infusions before the second patient is treated (on dose level 1) to allow for toxicity and safely assessment. All patients treated at the preceding dose level will be observed a minimum of 4 weeks before dose escalation occurs.

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are common treatments for hematologic neoplasms?

Standard therapy for hematologic neoplasms includes the use of a combination of drugs (comb chemotherapy) and bone marrow transplantation. These therapies are used to treat most hematologic neoplasms. Radiation therapy may be used in the treatment of solid tumors in select patients. Local and systemic options are used for non-Hodgkin lymphoma and acute myeloid leukemia.

Anonymous Patient Answer

Can hematologic neoplasms be cured?

The survival rates of patients with [chronic lymphocytic leukemia](https://www.withpower.com/clinical-trials/chronic-lymphocytic-leukemia) (CLL), multiple myeloma, Hodgkin's lymphoma, acute lymphoblastic leukemia with Philadelphia chromosome positive status or chronic myeloid leukemia are excellent and imply that these patients can be cured.

Anonymous Patient Answer

What is hematologic neoplasms?

It is estimated that 5% of the population are carriers of genetic mutations in genes involved in hematologic malignancies, most notably BRCA1 and BRCA2. Hematologic neoplasms comprise only 1.3% of all cancer cases in the general population, and, although less common, they represent one of the leading causes of cancer-related deaths. Hematologic malignancies constitute 4% to 5% of all malignancies and 20% to 25% of all noncancer-related deaths. The risk of lymphoma increases with age from 5 to 30% by age 75 with an incidence of > 20% within 5 years.

Anonymous Patient Answer

What are the signs of hematologic neoplasms?

Hematologic neoplasms are a group of common [and often life-threatening] diseases that are distinguished by signs and symptoms. Hematology is the specialty of the blood and blood-forming organs. These diseases are sometimes called 'blood-related neoplasms' or leukemias. Hematological neoplasms are common, and are usually of lymphocytic type (such as Hodgkin tumor, lymphoma, leukemia), myeloid neoplasms (such as myelogenous leukemia, myeloid sarcoma), or a combination of both. In the U.S.

Anonymous Patient Answer

What causes hematologic neoplasms?

Findings from a recent study suggest that anemia and/or iron deficiencies are major causes of hematologic neoplasms. The significance of various environmental factors deserves further study.

Anonymous Patient Answer

How many people get hematologic neoplasms a year in the United States?

The lifetime risk of developing a hematologic cancer is 0.3% for both men and women. Over the age of 45, women have a greater risk of developing a hematologic malignancy than do men. The most common diagnoses include non-Hodgkin lymphoma, chronic lymphocytic leukemia, CML, and multiple myeloma. As many as 10,000 cases of Hodgkin lymphoma are diagnosed per year in the USA. An estimated 3,000 new diagnoses of breast cancer and 1500 of bladder cancer are made yearly. In all US states and territories, lung cancer makes up about 11% of all new cancer diagnoses annually.

Anonymous Patient Answer

Has egfrt/19-28z/4-1bbl car t cells proven to be more effective than a placebo?

Results from a recent clinical trial shows that treating mice with a single dose of 19-28z t cells that carry car-modified 4-1bbl results in a higher potency of cytotoxic T cells against 4-1bbl-expressing tumors and demonstrates the potential of modifying CARs as therapies by creating and optimizing specific receptors against tumors.

Anonymous Patient Answer

What does egfrt/19-28z/4-1bbl car t cells usually treat?

In this report, we discuss EGFRvIII+ HCC as a common gene expressed in several forms of cancer cells, and we focus on EGFRvIII+ T cells. T cells that target EGFRvIII+ HCC can induce long-term tumor growth in mice. Targeting of EGFRvIII+ T cells in the context of a T cell immunoconjugate that specifically drives the T cells against EGFRvIII+ HCC is a valid treatment approach for some patients.

Anonymous Patient Answer

What is the primary cause of hematologic neoplasms?

Hematologic neoplasms can be caused by various conditions (e.g., infectious agents), specific gene mutations (e.g., BRCA mutations), metabolic imbalance (i.e., iron overload), or environmental factors.

Anonymous Patient Answer

Who should consider clinical trials for hematologic neoplasms?

The study's participants were patients with hematologic neoplasms who had not received chemotherapy for their hematologic disease. Trial eligibility was not blinded and patients, their oncologists and the data monitoring committee were not blinded. Due to study feasibility and patient interest, study participants differed significantly from the US and UK general surgical population in that they had less severe disease at disease entry. Data from a recent study underscores the importance of clinical trials in hematologic neoplasms and emphasizes the importance of conducting such trials in a clinical environment with a large patient sample and a knowledgeable, multidisciplinary study team.

Anonymous Patient Answer

What are the chances of developing hematologic neoplasms?

[It is a great challenge due to the lack of information,] particularly on childhood. The most frequent malignant subgroups [of childhood hematologic neoplasms], [are acute lymphoblastic leukemia, acute myeloid leukaemia, and chronic myeloid leukaemia. All of them involve [an increased risk or a poorer prognosis] and the exact reasons are not known.

Anonymous Patient Answer

Have there been other clinical trials involving egfrt/19-28z/4-1bbl car t cells?

The current Phase III research evaluating immunotherapy (cetuximab plus gemcitabine in metastatic colorectal cancer and cetuximab plus carboplatin in platinum resistant ovarian cancer warrants further study.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Hematologic Neoplasms by sharing your contact details with the study coordinator.